The iron chelator and OXPHOS inhibitor VLX600 induces mitophagy and an autophagy-dependent type of cell death in glioblastoma cells.


Journal

American journal of physiology. Cell physiology
ISSN: 1522-1563
Titre abrégé: Am J Physiol Cell Physiol
Pays: United States
ID NLM: 100901225

Informations de publication

Date de publication:
01 12 2023
Historique:
medline: 30 11 2023
pubmed: 30 10 2023
entrez: 30 10 2023
Statut: ppublish

Résumé

Induction of alternative, non-apoptotic cell death programs such as cell-lethal autophagy and mitophagy represent possible strategies to combat glioblastoma (GBM). Here we report that VLX600, a novel iron chelator and oxidative phosphorylation (OXPHOS) inhibitor, induces a caspase-independent type of cell death that is partially rescued in adherent U251

Identifiants

pubmed: 37899749
doi: 10.1152/ajpcell.00293.2023
doi:

Substances chimiques

VLX600 0
Antineoplastic Agents 0
Mitochondrial Proteins 0
Iron Chelating Agents 0
Iron E1UOL152H7
Proto-Oncogene Proteins c-bcl-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

C1451-C1469

Subventions

Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : 259130777

Auteurs

Lisa Reisbeck (L)

Experimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, Frankfurt am Main, Germany.

Benedikt Linder (B)

Experimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, Frankfurt am Main, Germany.

Georg Tascher (G)

Institute of Biochemistry II, Goethe University, Frankfurt am Main, Germany.

Süleyman Bozkurt (S)

Institute of Biochemistry II, Goethe University, Frankfurt am Main, Germany.

Katharina J Weber (KJ)

Neurological Institute (Edinger Institute), Goethe University Hospital, Frankfurt am Main, Germany.
Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany.
University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
German Cancer Consortium (DKTK), Partner site Frankfurt/Main, a partnership between DKFZ and University Hospital, Frankfurt, Germany.

Christel Herold-Mende (C)

Division of Experimental Neurosurgery, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany.

Sjoerd J L van Wijk (SJL)

Institute for Pediatric Hematology and Oncology, Goethe University Hospital Frankfurt/Main, Frankfurt am Main, Germany.
German Cancer Consortium (DKTK), Partner site Frankfurt/Main, a partnership between DKFZ and University Hospital, Frankfurt, Germany.

Rolf Marschalek (R)

Institute of Pharmaceutical Biology, Diagnostic Center of Acute Leukemia, University of Frankfurt, Frankfurt/Main, Germany.

Liliana Schaefer (L)

Institute of Pharmacology and Toxicology, Goethe University, Frankfurt, Germany.

Christian Münch (C)

Institute of Biochemistry II, Goethe University, Frankfurt am Main, Germany.

Donat Kögel (D)

Experimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, Frankfurt am Main, Germany.
German Cancer Consortium (DKTK), Partner site Frankfurt/Main, a partnership between DKFZ and University Hospital, Frankfurt, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH